Limits...
A generally applicable cost-effectiveness model for the evaluation of vaccines against cervical cancer.

Demarteau N, Detournay B, Tehard B, El Hasnaoui A, Standaert B - Int J Public Health (2010)

Bottom Line: Costs and outcomes (discounted at 3 and 1.5%, respectively) were compared with a cohort receiving screening alone.The model results agreed well with real-life data.Sensitivity analysis showed that the discount rate and the parameters related to the disease history have the largest impact on the results.

View Article: PubMed Central - PubMed

Affiliation: Health Economics, GlaxoSmithKline Biologicals, Wavre, Belgium. nadia.x.demarteau@gskbio.com

ABSTRACT

Objective: This study aimed at evaluating the cost-effectiveness of human papillomavirus virus (HPV) vaccination in France, using a generally applicable succinct cohort model.

Methods: A lifetime Markov cohort model, adapted to the French setting, simulate the natural history of oncogenic HPV infection towards cervical cancer (CC). Additional modules account for the effects of screening and vaccination. The girls' cohort is vaccinated at age 12 and follows current screening. Costs and outcomes (discounted at 3 and 1.5%, respectively) were compared with a cohort receiving screening alone.

Results: The model results agreed well with real-life data. Vaccination in addition to screening would substantially reduce the incidence of and mortality from CC, compared with screening alone, at an estimated cost-effectiveness of 9,706 per quality-adjusted-life-year. Sensitivity analysis showed that the discount rate and the parameters related to the disease history have the largest impact on the results.

Conclusion: This succinct cohort model indicated that HPV vaccination would be a cost-effective policy option in France. It uses readily available data and should be generally applicable to the evaluation of HPV vaccination in a variety of countries and settings.

Show MeSH

Related in: MedlinePlus

Incidence (top) and mortality (bottom) of invasive cervical cancer in France predicted by the model (squares) and observed by the French national cancer registry (Exbrayat 2002) (diamonds)
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3066388&req=5

Fig1: Incidence (top) and mortality (bottom) of invasive cervical cancer in France predicted by the model (squares) and observed by the French national cancer registry (Exbrayat 2002) (diamonds)

Mentions: As shown in Fig. 1, the model results closely matched the incidence and mortality data for invasive cervical cancer reported by the French national cancer registry (Exbrayat 2002) for women aged 60–65 years or less, although the model tends to underestimate cancer incidence and mortality at older ages.Fig. 1


A generally applicable cost-effectiveness model for the evaluation of vaccines against cervical cancer.

Demarteau N, Detournay B, Tehard B, El Hasnaoui A, Standaert B - Int J Public Health (2010)

Incidence (top) and mortality (bottom) of invasive cervical cancer in France predicted by the model (squares) and observed by the French national cancer registry (Exbrayat 2002) (diamonds)
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3066388&req=5

Fig1: Incidence (top) and mortality (bottom) of invasive cervical cancer in France predicted by the model (squares) and observed by the French national cancer registry (Exbrayat 2002) (diamonds)
Mentions: As shown in Fig. 1, the model results closely matched the incidence and mortality data for invasive cervical cancer reported by the French national cancer registry (Exbrayat 2002) for women aged 60–65 years or less, although the model tends to underestimate cancer incidence and mortality at older ages.Fig. 1

Bottom Line: Costs and outcomes (discounted at 3 and 1.5%, respectively) were compared with a cohort receiving screening alone.The model results agreed well with real-life data.Sensitivity analysis showed that the discount rate and the parameters related to the disease history have the largest impact on the results.

View Article: PubMed Central - PubMed

Affiliation: Health Economics, GlaxoSmithKline Biologicals, Wavre, Belgium. nadia.x.demarteau@gskbio.com

ABSTRACT

Objective: This study aimed at evaluating the cost-effectiveness of human papillomavirus virus (HPV) vaccination in France, using a generally applicable succinct cohort model.

Methods: A lifetime Markov cohort model, adapted to the French setting, simulate the natural history of oncogenic HPV infection towards cervical cancer (CC). Additional modules account for the effects of screening and vaccination. The girls' cohort is vaccinated at age 12 and follows current screening. Costs and outcomes (discounted at 3 and 1.5%, respectively) were compared with a cohort receiving screening alone.

Results: The model results agreed well with real-life data. Vaccination in addition to screening would substantially reduce the incidence of and mortality from CC, compared with screening alone, at an estimated cost-effectiveness of 9,706 per quality-adjusted-life-year. Sensitivity analysis showed that the discount rate and the parameters related to the disease history have the largest impact on the results.

Conclusion: This succinct cohort model indicated that HPV vaccination would be a cost-effective policy option in France. It uses readily available data and should be generally applicable to the evaluation of HPV vaccination in a variety of countries and settings.

Show MeSH
Related in: MedlinePlus